CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech treated the first patient in a pivotal Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with metastatic or locally advanced basal cell carcinoma (BCC). Curis and Genentech had previously disclosed the expected trial initiation in separate January announcements. Under the companies’ collaboration agreement, Curis will receive a $6 million cash payment from Genentech following initiation of this pivotal trial.
